Predictive value of Bcl-2 and Bax protein expression for chemotherapeutic effect in gastric cancer. A pilot study

Oncology

Volumn 55, Issue 6, 1998, Pages 543-547

  Nakata, Bunzo ^a   Muguruma, Kazuya ^a   Hirakawa, Kosei ^a   Chung, Y S ^a   Yamashita, Yoshito ^a   Inoue, Tohru ^a   Matsuoka, Tasuku ^a   Onoda, Naoyoshi ^a   Kato, Yasuyuki ^a   Sowa, Michio ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bax; Bcl 2; Chemotherapy; Gastric cancer

Indexed keywords

CISPLATIN; FLUOROURACIL; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; BIOPSY; CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; STOMACH CANCER;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; BIOPSY; CISPLATIN; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 0031756636     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011910     Document Type: Article

References (12)

1. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990;40:2353-2362.
2. Reed JC, Kitada S, Takayama S, Miyashita T: Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994;5(suppl 1):S61-S65.
3. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995;55: 4471-4478.
4. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB, Korsmeyer SJ: Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995;92:7834-7838.
5. Thomas A, El-Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996;12:1055-1062.
6. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programed cell death. Cell 1993;74:609-619.
7. Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma, English ed 1. Tokyo, Kanehara, 1995.
8. Chung YS, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Onoda N, Maeda K, Sawada T, Kato Y, Shirasaka T, Sowa M: Continuous 5-FU and low dose cisplatin for advanced and recurrent gastric cancer. Cancer 1997;80:1-7.
9. Hamberger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 1977;197: 461-463.
10. Kondo T, Imamura T, Ichihashi H: In vitro test for sensitivity of tumor to carcinostatic agents. Gann 1966;57:113-121.
11. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74: 957-967.
12. Yin XM, Oltvai ZN, Korsmeyer SJ: BH-1 and BH-2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321-323.